(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 132.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Connect Biopharma Holdings's revenue in 2025 is $1,965,000.On average, 2 Wall Street analysts forecast CNTB's revenue for 2026 to be $835,824,855, with the lowest CNTB revenue forecast at $557,216,570, and the highest CNTB revenue forecast at $1,114,433,140. On average, 2 Wall Street analysts forecast CNTB's revenue for 2027 to be $1,379,111,011, with the lowest CNTB revenue forecast at $835,824,855, and the highest CNTB revenue forecast at $1,922,397,167.
In 2028, CNTB is forecast to generate $1,298,314,608 in revenue, with the lowest revenue forecast at $378,907,268 and the highest revenue forecast at $2,217,721,949.